Transgene Biotek Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2025 ,inter alia, to consider and approve 1) To consider and approve ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Transgene Biotek has called a Board Meeting on August 7, 2025 to consider and approve its Un-Audited Standalone and Consolidated Financial Results for Q1 FY26 (quarter ended June 30, 2025). The Board will also consider extending the Annual General Meeting (AGM) for FY 2024-25, which suggests the company may not hold the AGM within the standard deadline. Additionally, the Board will appoint Geeta Serwani & Associates as Secretarial Auditor and an internal auditor for FY 2024-25. The trading window for insiders has been closed since July 1, 2025 and will reopen 48 hours after the Q1 results are publicly available.
Investors should watch for the Q1 FY26 results announcement on August 7, which could move the stock based on earnings performance. The AGM extension may raise minor governance concerns but is often a routine compliance matter. No material financial impact can be assessed until the actual results are published.